Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOS-342 in advanced hepatocellular carcinoma and other GPC3-expressing tumors
ACTRN12623000798662Phase 2Terminated
- Sponsor
- Boston Pharmaceuticals
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of PRS-342 in hepatocellular carcinoma (HCC) and Nonhematologic neoplasms (2 arms), sponsored by Boston Pharmaceuticals. Primary endpoints: Occurrence of dose-limiting toxicities, Incidence of TEAEs, TRAEs, SAEs, and Grade 3 or higher TEAEs and 3 more. Started Aug 2023; status: terminated.
02
Drugs
PRS-342
03
Conditions
hepatocellular carcinoma (HCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ACTRN12623000798662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000798662.